In particular, four of the eight candidate compounds in pancreatic cancer were MTOR-targeting drugs and were significantly more effective in EIF3C mutated cell lines than WT cell lines (Supplementary Data 3). The gene discussed is MTOR; the disease is familial pancreatic carcinoma.